Covid-19 action plan – 2021 update - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.

aProximateTM

Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Published 13th January 2021 | News

Covid-19 action plan – 2021 update

In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and our wider community from the Covid-19 virus.

We have reviewed our policies and procedures in light of the recent Government restrictions and implemented further measures including improved physical barriers, biosecurity procedures and work patterns to enable us to continue servicing our customers while maintaining the safety of our staff.

We wish all of our customers, suppliers and partners a safe and healthy 2021.

Dr Mike Nicholds
CEO
Newcells Biotech

A message to our customers, collaboration partners and colleagues

Share This:
Tweet Post Share